Legal Representation
Attorney
Bret E. Field
USPTO Deadlines
Next Deadline
2827 days remaining
Section 71 Renewal Due (Principal Register 66a) (Based on registration date 20131015)
Due Date
October 15, 2033
Grace Period Ends
April 15, 2034
Application History
42 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| May 28, 2024 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| May 28, 2024 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| May 28, 2024 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| May 11, 2024 | NA75 | E | NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED | Loading... |
| May 11, 2024 | C75A | O | REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK. | Loading... |
| May 7, 2024 | APRE | A | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | Loading... |
| Sep 15, 2023 | ES75 | I | TEAS SECTION 71 & 15 RECEIVED | Loading... |
| Oct 15, 2022 | REM4 | E | COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED | Loading... |
| Oct 6, 2022 | RNWL | P | INTERNATIONAL REGISTRATION RENEWED | Loading... |
| Oct 17, 2020 | INNP | P | PARTIAL INVALIDATION PROCESSED BY THE IB | Loading... |
| Sep 5, 2020 | INPS | P | PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | Loading... |
| Aug 26, 2020 | INPC | P | INVALIDATION PROCESSED | Loading... |
| Jul 21, 2020 | INPR | P | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | Loading... |
| Nov 21, 2019 | NA75 | E | NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED | Loading... |
| Nov 21, 2019 | C75P | O | REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK. | Loading... |
| Nov 21, 2019 | APRE | A | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | Loading... |
| Oct 14, 2019 | ES75 | I | TEAS SECTION 71 & 15 RECEIVED | Loading... |
| Oct 15, 2018 | REM3 | E | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | Loading... |
| Jan 9, 2017 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Apr 10, 2014 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB | Loading... |
| Mar 3, 2014 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB | Loading... |
| Mar 3, 2014 | FIMP | P | FINAL DISPOSITION PROCESSED | Loading... |
| Jan 15, 2014 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... |
| Oct 15, 2013 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Jul 30, 2013 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jul 10, 2013 | NPUB | O | NOTICE OF PUBLICATION | Loading... |
| Jun 24, 2013 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
| Jun 17, 2013 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| May 30, 2013 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| May 30, 2013 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| May 22, 2013 | ALIE | A | ASSIGNED TO LIE | Loading... |
| May 20, 2013 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| May 11, 2013 | CHLD | M | CHANGE OF OWNER RECEIVED FROM IB | Loading... |
| Feb 27, 2013 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Jan 28, 2013 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| Jan 28, 2013 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| Jan 26, 2013 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| Jan 25, 2013 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jan 18, 2013 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jan 15, 2013 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Jan 9, 2013 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jan 3, 2013 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 005
Pharmaceuticals for the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditions; pharmaceutical preparations, compositions, creams and lotions for the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditions; prescription and over-the-counter pharmaceutical preparations for the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditions; prescription and over-the-counter pharmaceutical preparations, namely, transdermal gel formulations, transdermal cream formulations, oral mucous formulations, transdermal patches, dressings and medical adhesive tapes for use in the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditions
Class 042
Pharmaceutical research and development; pharmaceutical product evaluation, testing and inspection services; providing medical and scientific research information in the field of pharmaceuticals; information, advisory and consultancy services relating to all the aforesaid services
Additional Information
Color Claim
Color is not claimed as a feature of the mark.
Translation
The English translation of "TEIKOKU" in the mark is "EMPIRE".
Classification
International Classes
005
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"PHARMA"